The pre-proglucagon derived peptides, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are both involved in a wide variety of peripheral functions, such as glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. Pre-proglucagon is also found in the brainstem in a small population of nerve cells in the nucleus of the solitary tract (NTS) that process the pre-propeptide as in the gut to yield GLP-1 and GLP-2. GLP-1 containing nerve fibres and the GLP-1 receptor are found predominantly in hypothalamic midline nuclei. GLP-1 given centrally to naive rats results in a marked induction of c-Fos protein in the supraoptic nucleus, paraventricular nucleus of the hypothalamus (PVN) and central nucleus of the amygdala, but only a moderate increase in the arcuate nucleus. The pattern of c-Fos activation is compatible with the appetite suppressing effects of GLP-1. This anorectic effect of GLP-1 appears to be mediated by the PVN, as direct injections of GLP-1 into this nucleus cause anorexia without concomitant taste aversion, suggesting a specific action upon neuronal circuits involved in the regulation of feeding. Recent experiments have also shown that GLP-1 is implicated in mediating signals from the gastrointestinal tract pertaining to discomfort and malaise. The distribution of the co-localised peptide, GLP-2, displays a perfect overlap with GLP-1 in the CNS with the highest concentration in the diffuse ventral part of the dorsomedial nucleus (DMHv). In contrast to the widely distributed GLP-1 receptor mRNA, GLP-2 receptor mRNA is exclusively expressed in the compact part of the DMH (DMHc). Interestingly, the DMHc is also the only nucleus responding to central administration of GLP-2 with a significant increase in the number of c-Fos positive cells. When injected into the lateral ventricle, GLP-2 has a marked inhibitory effect on feeding. The effect of GLP-2 on feeding is both behaviourally and pharmacologically specific. Future experiments will elucidate whether or not GLP-1 and GLP-2 are involved in the long-term or short-term regulation of feeding behaviour and hence have an impact on bodyweight.
Introduction
Glucagon-like peptide-1 and 2 (GLP-1 and GLP-2) are derived from the pre-prohormone, pre-proglucagon. Pre -proglucagon is expressed in pancreatic A-cell and the L-cells of the gut as well as in the caudal part of the nucleus of the solitary tract (NTS). The post-translational processing of pre -proglucagon in the gut and brain is similar and gives rise to GLP-1, GLP-2 and glicentin as the three main end products ( Figure  1 ).
In the periphery GLP-1 and GLP-2 have a number of distinct functions. By specific interaction with the GLP-1 receptor on the pancreatic beta cell, GLP-1 has proven to be a potent insulinotropic peptide both in vitro and in vivo. 1 -3 In humans and rats it has been shown that GLP-1 inhibits gastric acid secretion as well as gastric motility. 4, 5 Furthermore, it has recently been reported that peripheral GLP-1 affects appetite. Continuous infusion of GLP-1 in both normal and obese humans coinciding with the presentation of food inhibits energy intake and induces satiety and fullness as assessed using VAS (visual analogue scale) scores. 6 However, it is still disputed as to whether the effect seen is due to interaction with GLP-1 receptors involved in gastric motility or to interaction with GLP-1 receptors located in the central nervous system.
Until recently, the second product of the post-translational processing of preproglucagon, GLP-2, had no assigned function. However, it has now been demonstrated that GLP-2 in the periphery exerts trophic effects on the large and small bowel epithelium via stimulation of cell proliferation and inhibition of apoptosis. 7 In addition, GLP-2 up-regulates intestinal glucose transporter activity and inhibits gastric acid secretion and gastric motility. 7 To date no physiological functions of glicentin have been described.
In the brain, GLP-1 and GLP-2 are synthesised exclusively in the non-catecholaminergic and leptin receptor positive neurones of the nucleus of the solitary tract (NTS) and the dorsal and ventral part of the reticular nucleus 8 -10 ( Figure 2 ). The GLP-1 neurones are localised in the caudal portion of the NTS, receiving afferents from the gastrointestinal and cardiovascular system via the vagal and glossopharyngeal nerves. This portion of the NTS serves as an integrative site relaying sensory information to fore-, mid-and brainstem centres involved in the regulation of digestion and cardiac output. 8, 9 A large number of hypothalamic nuclei contain GLP-1=GLP-2 immunoreactive (-IR) fibres. The highest densities of GLP-1=GLP-2-IR fibres are found in the PVN and in the ventral diffuse part of the dorsomedial hypothalamic nucleus (DMHv), whereas the hypothalamic arcuate nucleus is less densely innervated. 8, 9 Glucagon-like peptide-1 receptor (GLP-1R) mRNA is widely expressed in the hypothalamus. In particular, the supraoptic (SON), arcuate paraventricular (PVN) and dorsomedial (DMH) nuclei are enriched with GLP-1R mRNA (Figure 3a , c, e). Additionally, receptor autoradiographic studies have demonstrated high densities of GLP-1 binding sites in the same hypothalamic nuclei as well as in sensory circumventricular organs including the subfornical organ (SFO), organum vasculosum laminae terminalis (OVLT) and area postrema (AP). 11 In contrast to the widely distributed GLP-1 receptor, GLP-2 receptor mRNA and GLP-2 receptor immunoreactivity are only found in the compact part of the dorsomedial nucleus (DMHc; Figure 3f ). 12 The distribution of GLP-1 and GLP-2 neurons, fibres and receptors in the CNS points to a role of the GLP-system in the regulation of feeding behaviour and metabolism. In this short paper the role our current knowledge of GLP-1 and GLP-2 will be reviewed. 
Materials and methods
Animals and surgery Seventy-two male rats weighing between 240 and 275 g were used in the experiments. Animals were fitted with a stainless steel cannula (gauge 22) inserted into the lateral ventricle using a standard surgical paradigm. Cannula placement was confirmed using the Angiotensin II paradigm (for further details see Tang-Christensen et al 13 ). After post-surgical recovery of 7 days, rats were housed individually in metabolic cages for precise measurements of food and water intake. To accustom the animals to the experimental procedure, all rats were handled daily. All experiments were conducted in accordance with internationally accepted principles for the care and use of laboratory animals and approved by the Danish Committee for Animal Research.
Fasting feeding assay
Rats were subjected to a 16 h fast (water available ad libitum), before injections with 10 ml either vehicle (PBS, 50 mM, pH 7.4) or various cocktails of peptides (see Figure 4 ). When not otherwise stated, the dose given of either GLP-1 or GLP-2 was 10 mg GLP-1 (7 -36) amide (Bachem, Bubendorf, Switzerland), a dose previously shown to maximally inhibit food intake in rats. 13 
NPY-induced feeding assay
Five groups of 1 h food deprived control rats were used (n ¼ 6 -10 in each group). Rats were cannulated as described above and were kept on a free-feeding regimen.
On the experimentation day rats were randomized to five groups, all of which received an injection of 5 mg of neuropeptide Y (NPY; Peninsula, London, UK). Fifteen minutes prior to the NPY injection the first group of rats received 5 ml of vehicle icv. The second group received 10 mg GLP-1 (7 -36) amide in 5 ml. The third group received a 10 mg injection of GLP-2 (1 -33) and finally, the fourth group received an injection of 10 mg of GLP-2 (5 -33) prior to the NPY injection. Food intake was measured 1 h after the last injection.
Drinking assays: angiotensin II assay
The effect of angiotensin II (AII) on drinking behaviour in rats has been well described.
14 An i.c.v. injection of A II induces a robust water intake and hence is useful when Figure 3 The GLP-1 receptor mRNA is distributed throughout the content of the hypothalamus (a, c and e); notably there is intense labelling of the supraoptic nucleus (SON) (a), paraventricular (PVN) and arcuate (Arc) nucleus (c), and the dorsomedial hypothalamic nucleus DMH (e). In contrast GLP-2 receptor mRNA was in the hypothalamus exclusively located at the DMH (f) and interestingly not in the PVN or the Arc (d). Regulation of feeding behaviour M Tang-Christensen et al testing the adipsogenic effect of other compounds. Just prior to the administration of 50 ng AII rats were given one of the following i.c.v. injections in 5 ml vehicle: vehicle; 10 mg GLP-1 (1 -36); 10 mg GLP-1 (7 -36); 10 mg Exendin (9 -39) þ 2 mg GLP-1 (7 -36); GLP-2 mg (1 -33) ; or 10 mg GLP-2 (5 -33; Table  1 ). Water intake was measured 1 h after administration of AII.
Results

Feeding assays
Fasting-induced feeding behaviour. GLP-1: central administration of increasing doses of GLP-1 resulted in a dosedependent reduction in feeding behaviour, the lowest dose being 5 mg (Figure 4a ). The non-truncated form of GLP-1, GLP-1 (1 -36), which has been shown to be inactive at the pancreatic GLP-1 receptor, did not alter food intake. The anorectic effect of 1 mg GLP-1 (7 -36) was reversed by prior administration of the GLP-1 receptor antagonist, Exendin (9 -39; 10 -mg) to the level of the vehicle-injected animals ( Figure 4a ). Interestingly, this dose of Exendin (9 -39) did not by itself cause any alterations in feeding behaviour when administered on its own (Figure 4a ).
GLP-2: central administration of 10 mg GLP-2 (1 -33) significantly decreased food intake by approximately 35% in 16 h fasted rats when compared to vehicle injected animals (Figure 4b).
NPY-induced feeding behaviour. Central administration of 10 mg of GLP-1 (7 -36) significantly decreased NPY-induced food intake by approximately 50%, when compared to vehicle-injected animals (Figure 4c ). Central administration of GLP-2 (1 -33) also resulted in a 50% decrease when compared to vehicle injected controls whereas the animals that received the truncated GLP-2 analogue, GLP-2 (5 -33) had no decrease in food intake when compared to vehicle injected animals (Figure 4c ).
Drinking assays: AII-induced drinking
Central as well as peripheral administration of GLP-1 (7 -36) resulted in a robust reduction in AII-induced drinking. This effect was pharmacologically specific since a similar dose of the non-truncated GLP-1 analogue, GLP-1 (1 -36), had no effect on AII-induced drinking, and the adipsogenic properties of central administered GLP-1 (7 -36) were reversed by prior administration of the GLP-1 receptor antagonist, Exendin (9 -39; Table 1 ). Central administration of GLP-2 did not result in any alterations in AII-induced drinking.
Discussion
GLP-1
In addition to well-known peripheral actions we have demonstrated a powerful role of GLP-1 as a central anorectic and adipsogenic agent. 15, 16 In later studies 17 we examined the effect of GLP-1 in animals bearing neurochemical lesions of the arcuate nucleus (MSG-treatment). Neonatal MSGtreatment completely abolished the central anorectic effect of GLP-1, suggesting that the neurons of the arcuate nucleus are involved in mediating the effects of GLP-1 on appetite. 17 As demonstrated by Thiele et al, sensitive assays of conditioned taste aversion (CTA) have shown transient CTA in rats injected centrally with high doses of GLP-1. 18 Thus, it is possible that GLP-1 inhibits feeding by causing nausea rather than via a specific effect on satiety. In line with this, the lack of effect of GLP-1 in MSG-rats could be a result of abolished sensitivity to taste aversion. However, MSG-rats displayed full sensitivity to conditioned taste aversion, suggesting that ablation of the arcuate nucleus interferes with GLP-1-induced anorexia. 17 The fact that GLP-1 failed to suppress NPY induced feeding in MSG-rats suggests that GLP-1 interacts with inhibitory arcuate neurons with projections to distant hypothalamic neurones mediating NPY-induced feeding behaviour ( Figure  5 ). Apparently GLP-1 does not act on the NPY neurons per se as NPY-induced feeding can be attenuated in intact animals by prior administration of GLP-1. As depicted in Figure 5 , the most likely GLP-1 sensitive target mediating the inhibitory effect of GLP-1 upon feeding is a pathway from the arcuate nucleus (Arc) to the PVN organised in parallel to the NPYergic connection between these hypothalamic nucleipossibly the POMC=CART neurons. However, this hypothesis needs to be tested in future studies.
GLP-2
Like GLP-1, GLP-2 has turned out to be a neurotransmitter with a potent effect on food intake. However, in contrast to GLP-1, GLP-2 only suppressed food intake, and not water intake. Given the widespread distribution of central GLP-1 receptors and the structural similarities between GLP-1 and GLP-2, the possible interaction of GLP-2 with GLP-1 receptors should be considered. However, in an in vitro assay, GLP-2 has been shown not to bind to the GLP-1 receptor. 15 In Table 1 The effect of glucagon-like peptides on angiotensin II-induced drinking in rats Peptides i.c.v. injection, 10 ml i.p. injection, 500 ml The effect of centrally administered glucagon-like peptides on drinking behaviour in an Ang II induced drinking assay. A 50 ng AII injection was preceeded by an injection of various cocktails of peptides in 5 ml vehicle. Water intake (ml) was measured 2-h after the injection of AII. All data are expressed as mean þ s.e.m., with n ¼ 7 -14. NA ¼ not assessed.
Regulation of feeding behaviour M Tang-Christensen et al addition GLP-2 receptors are insensitive to GLP-1. We have examined the interaction between GLP-2 and Exendin (9 -39), a compound derived from the venom of the gila monster (Helodermum suspectum). Although Exendin (9 -39) is a GLP-1 receptor antagonist, it also interferes with GLP-2 receptor signalling, as Exendin (9 -39) administration completely blocks the anorectic effect of GLP-2. 12 Lacking a fully functional GLP-2 receptor assay, we were unable to address the nature of the functional antagonism exerted by Exendin (9 -39) upon the action of GLP-2. However, it seems unlikely that Exendin (9 -39) binds directly to the GLP-2 receptor and a more likely explanation is that Exendin (9 -39) acts as a functional GLP-2 receptor antagonist. In any case these data warrant an evaluation of the interaction between these two pre-proglucagon-derived peptides.
The dense plexus of GLP-2 immunoreactive fibres, the exclusivity of the hypothalamic GLP-2 receptor mRNA and GLP-2 induced c-Fos in the DMH is highly interesting. The DMH is centrally involved in rheostatic mechanisms maintaining a relatively constant body weight. The DMH receives inputs from the Arc and ventromedial (VMN) nuclei and in turn feeds input to the parvocellular part of the PVN. Furthermore, this DMH-PVN projection has been shown to play an important role in the regulation of food intake and bodyweight and to be essential in neuroendocrine and autonomic homeostasis. 19 Finally, the DMH, VMN and the Arc nuclei all respond to circulating levels of leptin. Our data therefore point to the DMH as a crossroad for endocrine and visceral information affecting feeding behaviour.
Although the phenotype of the DMH neurones responding to GLP-2 is unknown, NPY-expressing neurons could be involved. Although the majority of NPY positive cells within the hypothalamus are located in the Arc nucleus, a small number of scattered NPY cells are located in the DMH. Notably, NPY expression in this population of neurones have been shown to be up-regulated under circumstances characterised by increased caloric demand such as suckling and fasting. 20, 21 We and others have demonstrated that the pre-proglucagon fragments, GLP-1 and GLP-2, expressed in the central nervous system are profoundly involved in the regulation of feeding behaviour. Pre-proglucagon expressing neurones of the NTS also express the long form of the leptin receptor suggesting an interaction between adipocytes and central GLP-1 and GLP-2 neurotransmission. 10 However, the functional implications of a widespread GLP-1 system and a distinct GLP-2 system are poorly understood. It is our hope that future experiments will clarify the relative importance of GLP-1 and GLP-2 systems in the regulation of both longterm and short-term satiety as well as feeding behaviour.
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